Piracetam Plus Lecithin Trials in Senile Dementia of the Alzheimer Type

Samorajski, T.; Vroulis, George; Smith, Robert C.

doi:10.1111/j.1749-6632.1985.tb37616.x

Cited by 11 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Substrate loading with lecithin or choline has been tried with little improvement (Etienne et al, 1978(Etienne et al, , 1981Summers et al, 1981 ;Thal et al, 1981;Kaye et al, 1982;Pomara et al, 1983;Smith et al, 1984;Samorajski, Vroulis and Smith, 1985;Growdon et al, 1986) despite initial promise (Levy, 1978;Brinkman et al, 1982a,b;Canter, Hallett and Growdon, 1982;Little et al, 1985).…”

Section: Substrate Loadingmentioning

confidence: 94%

The treatment of Alzheimer's disease

Allen

Burns

1995

J Psychopharmacol

View full text Add to dashboard Cite

Section: Substrate Loadingmentioning

confidence: 94%

The treatment of Alzheimer's disease

Allen

Burns

1995

J Psychopharmacol

View full text Add to dashboard Cite

“…Piracetam combined with lecithin is being used in AD patients and phase III clinical study of piracetam in demented patients has demonstrated some degree of therapeutic efficacy [106,107]. Specific combination of piracetam and choline enhanced habituation of exploratory activity in mice [108].…”

Section: Classification Of Nootropicsmentioning

confidence: 99%

Towards Better Brain Management: Nootropics

Malik¹,

Sangwan²,

Saihgal³

et al. 2007

CMC

View full text Add to dashboard Cite

The learning and memory deficits have been recognized as severe and consistent neurological disorders associated with numerous neurodegenerative states. Research in this area has gained momentum only in the recent past after the biochemical and physiological basis of these processes have been understood. A considerable alteration in the neurotransmission is a consistent finding in cognitive disorders. Therefore, many therapeutic strategies to augment the concentration of neurotransmitters in brain such as cholinergic agents, biogenic amines and neuropeptides etc. have been evaluated in cognitive deficits. CNS modulators are the type of antiamnesics that act via modulation of the neurological processes underlying memory storage. These include psychostimulants, excitatory amino acids and most important of all "nootropics". Nootropics are a heterogeneous group of compounds of diverse chemical composition and biological function that allegedly facilitate learning and memory or overcome natural or induced cognitive impairments. The literature survey incorporated in this article hallmarks the success achieved in the design and development of potential nootropic agents. Additionally, this review is an attempt towards discussing various approaches available to enhance memory, along with the classification of the known memory enhancers, authors research work towards various structural modifications carried out and the biological screening.

show abstract

Piracetam for dementia or cognitive impairment

Flicker

Evans

2004

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Piracetam Plus Lecithin Trials in Senile Dementia of the Alzheimer Type

Cited by 11 publications

References 5 publications

The treatment of Alzheimer's disease

The treatment of Alzheimer's disease

Towards Better Brain Management: Nootropics

Piracetam for dementia or cognitive impairment

Contact Info

Product

Resources

About